Paul V. Viscuse

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study

Paul V. Viscuse, Katharine A. Price, Joaquín J. García et al. · Frontiers in Oncology · 2019 · 52 citations · Full text

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

Paul V. Viscuse, Mario L. Marques‐Piubelli, Meghan Heberton et al. · Frontiers in Oncology · 2021 · 47 citations · Full text

Pathology, Immune Profiling, Dermatology +17

Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer

Somaira Nowsheen, Paul V. Viscuse, Ciara C. O’Sullivan et al. · Current Breast Cancer Reports · 2017 · 42 citations · Full text

Breast Oncology, Medicine, Pharmacology +6

Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components

Rama Soundararajan, Paul V. Viscuse, Patrick G. Pilié et al. · Cancers · 2022 · 22 citations · Full text

Engineering, Genotype-to-phenotype Associations, Genetics +17

Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer

Daniel Westaby, Paul V. Viscuse, Rahul Ravilla et al. · American Society of Clinical Oncology Educational Book · 2021 · 17 citations · Full text

New Avengers, Androgen Receptor, Urology +11